I. Boucot

1.2k total citations
55 papers, 891 citations indexed

About

I. Boucot is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Epidemiology. According to data from OpenAlex, I. Boucot has authored 55 papers receiving a total of 891 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pulmonary and Respiratory Medicine, 24 papers in Physiology and 13 papers in Epidemiology. Recurrent topics in I. Boucot's work include Chronic Obstructive Pulmonary Disease (COPD) Research (26 papers), Asthma and respiratory diseases (24 papers) and Respiratory and Cough-Related Research (13 papers). I. Boucot is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (26 papers), Asthma and respiratory diseases (24 papers) and Respiratory and Cough-Related Research (13 papers). I. Boucot collaborates with scholars based in France, United States and Germany. I. Boucot's co-authors include C. Pribil, Patrick Berche, D. Huas, J. de Blic, B. Barry, P Géhanno, Lee Tombs, David A. Lipson, Ian Naya and Philippe Godard and has published in prestigious journals such as CHEST Journal, Journal of Clinical Microbiology and Annals of the Rheumatic Diseases.

In The Last Decade

I. Boucot

53 papers receiving 864 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
I. Boucot France 16 529 369 194 125 82 55 891
Francesco Menzella Italy 21 702 1.3× 830 2.2× 133 0.7× 112 0.9× 183 2.2× 104 1.3k
Marek Kulus Poland 16 592 1.1× 587 1.6× 193 1.0× 48 0.4× 97 1.2× 87 1.2k
Anne Putto‐Laurila Finland 13 200 0.4× 82 0.2× 366 1.9× 61 0.5× 102 1.2× 24 1.4k
Jacques Chrétien France 13 509 1.0× 185 0.5× 188 1.0× 53 0.4× 45 0.5× 21 830
Shahid Sheikh United States 19 737 1.4× 280 0.8× 154 0.8× 13 0.1× 69 0.8× 79 1.1k
Shreyas Gandhi Canada 11 113 0.2× 184 0.5× 278 1.4× 34 0.3× 36 0.4× 20 875
J. Angrill Spain 16 986 1.9× 216 0.6× 534 2.8× 9 0.1× 42 0.5× 24 1.4k
M. Plit Australia 20 579 1.1× 106 0.3× 486 2.5× 9 0.1× 48 0.6× 74 1.4k
Valeria Daccò Italy 17 363 0.7× 55 0.1× 233 1.2× 27 0.2× 81 1.0× 58 1.1k
Xavier Pomares Spain 19 753 1.4× 316 0.9× 166 0.9× 11 0.1× 37 0.5× 52 1.0k

Countries citing papers authored by I. Boucot

Since Specialization
Citations

This map shows the geographic impact of I. Boucot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Boucot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Boucot more than expected).

Fields of papers citing papers by I. Boucot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Boucot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Boucot. The network helps show where I. Boucot may publish in the future.

Co-authorship network of co-authors of I. Boucot

This figure shows the co-authorship network connecting the top 25 collaborators of I. Boucot. A scholar is included among the top collaborators of I. Boucot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Boucot. I. Boucot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Singh, Dave, James F. Donohue, I. Boucot, et al.. (2021). Future concepts in bronchodilation for COPD: dual-versusmonotherapy. European Respiratory Review. 30(160). 210023–210023. 7 indexed citations
2.
Bjermer, Leif, I. Boucot, Claus Vogelmeier, et al.. (2021). Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial. Advances in Therapy. 38(9). 4815–4835. 4 indexed citations
3.
Vogelmeier, Claus, Paul Jones, Edward Kerwin, et al.. (2021). Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial. Respiratory Research. 22(1). 279–279. 4 indexed citations
4.
Maltais, François, Ian Naya, Claus Vogelmeier, et al.. (2020). Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial. Respiratory Research. 21(1). 280–280. 10 indexed citations
5.
Naya, Ian, Lee Tombs, David A. Lipson, I. Boucot, & Chris Compton. (2019). Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis. Respiratory Research. 20(1). 60–60. 10 indexed citations
6.
Woodcock, Ashley, I. Boucot, David Leather, et al.. (2018). Effectiveness versus efficacy trials in COPD: how study design influences outcomes and applicability. European Respiratory Journal. 51(2). 1701531–1701531. 27 indexed citations
7.
Tombs, Lee, Michael J. Asmus, I. Boucot, et al.. (2018). Efficacy of Umeclidinium/Vilanterol in Elderly Patients with COPD: A Pooled Analysis of Randomized Controlled Trials. Drugs & Aging. 35(7). 637–647. 5 indexed citations
8.
Roche, Nicolás, C. Pribil, Philippe Devillier, et al.. (2015). Limited treatment adaptation despite poor asthma control in asthma patients treated with inhaled corticosteroids. Journal of Asthma. 53(1). 76–85. 7 indexed citations
9.
Amoura, Zahir, C. Deligny, M. Hamidou, et al.. (2014). Coût du lupus systémique en France des patients adultes avec une maladie active et traitée (étude LUCIE). La Revue de Médecine Interne. 35(11). 700–708. 2 indexed citations
10.
Roche, Nicolás, C. Pribil, Éric Van Ganse, et al.. (2014). Real-life use of fluticasone propionate/salmeterol in patients with chronic obstructive pulmonary disease: a French observational study. BMC Pulmonary Medicine. 14(1). 56–56. 26 indexed citations
11.
Doria, Andrea, Zahir Amoura, Ricard Cervera, et al.. (2012). Annual direct medical cost of active systemic lupus erythematosus in five European countries. Annals of the Rheumatic Diseases. 73(1). 154–160. 66 indexed citations
12.
Godard, Philippe, I. Boucot, C. Pribil, & D. Huas. (2010). Phénotype des patients asthmatiques selon le score dérivé de l’Asthma Control Test®. Revue des Maladies Respiratoires. 27(9). 1039–1048. 3 indexed citations
13.
Blic, J. de, I. Boucot, C. Pribil, et al.. (2009). Control of asthma in children: still unacceptable? A French cross-sectional study. Respiratory Medicine. 103(9). 1383–1391. 41 indexed citations
14.
Godard, Philippe, et al.. (2005). ER’Asthme, contrôle de l’asthme chez 16580 patients suivis en médecine générale. La Presse Médicale. 34(19). 1351–1357. 49 indexed citations
15.
Piperno, D, Gérard Huchon, C. Pribil, I. Boucot, & Thomas Similowski. (2003). The burden of COPD in France: results from the confronting COPD survey. Respiratory Medicine. 97. S33–S42. 35 indexed citations
16.
Bricaire, François, et al.. (2002). PATIENT PERSPECTIVE ON ZANAMIVIR IN THE TREATMENT OF INFLUENZA. International Journal of Clinical Practice. 56(1). 7–10. 2 indexed citations
17.
Géhanno, P, G. Lenoir, B. Barry, et al.. (1996). Evaluation of nasopharyngeal cultures for bacteriologic assessment of acute otitis media in children. The Pediatric Infectious Disease Journal. 15(4). 329–332. 68 indexed citations
18.
Barry, B., et al.. (1994). Clinical Outcome of Acute Otitis Media Caused by Pneumococci with Decreased Susceptibility to Penicillin. Scandinavian Journal of Infectious Diseases. 26(4). 446–452. 29 indexed citations
19.
Boucot, I., et al.. (1992). [Bacterial epidemiology of acute otitis media].. PubMed. 39(8). 485–90. 3 indexed citations
20.
Géhanno, P, et al.. (1991). Clinical Efficacy and Tolerability of Cefixime in the Treatment of Acute Sinusitis. Drugs. 42(Supplement 4). 19–24. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesco Menzella Breakdown of academic impact, for papers by Marek Kulus Breakdown of academic impact, for papers by Anne Putto‐Laurila Breakdown of academic impact, for papers by Jacques Chrétien Breakdown of academic impact, for papers by Shahid Sheikh Breakdown of academic impact, for papers by Shreyas Gandhi Breakdown of academic impact, for papers by J. Angrill Breakdown of academic impact, for papers by M. Plit Breakdown of academic impact, for papers by Valeria Daccò Breakdown of academic impact, for papers by Xavier Pomares
Rankless by CCL
2026